How Disc Medicine’s New HR Chief and Bitopertin Review Could Shape IRON’s Commercial Readiness
- Disc Medicine has appointed Lisa Amaya Price, an HR leader with more than 25 years of experience at global biopharma and life science companies, as its Chief Human Resources Officer to support the organization’s transition toward commercialization while the bitopertin new drug application remains under US FDA review.
- This combination of senior HR leadership and an advanced regulatory pipeline highlights how Disc Medicine is building the internal infrastructure required to support potential commercialization in serious hematologic diseases.
- We’ll now examine how adding an experienced Chief Human Resources Officer shapes Disc Medicine’s investment narrative as it advances bitopertin toward potential approval.
Trump has pledged to…
